Logo Icon
OrthoLength Pro Clinical & Patient Community
Log in Register
MEDICAL DISCLAIMER: The information provided on OrthoLength Pro is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified orthopedic surgeon.
Fact Checked by Clinical Team Study Summary

Femoroacetabular Impingement Syndrome

Be
Beddows TPA, Munnik-Hagewoud R...
February 05, 2026
0 views
View on PubMed
6 min read 1,016 words femoroacetabular impingement syndrome Medically Reviewed

Overview

Femoroacetabular impingement syndrome (FAIS) is a common cause of hip pain in young, active adults. The condition occurs when the ball and socket of the hip joint do not fit together perfectly, causing friction and potentially leading to avascular necrosis or osteoarthritis. A recent study published on professional female football players found that the prevalence of FAIS is low, while the prevalence of primary cam morphology is relatively high (Source: PubMed).

The study examined the relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology in professional female football players. The findings of this study are significant, as they suggest that the aetiology of FAIS and primary cam morphology in female football players may not be solely driven by high load activity during skeletal maturation, but is likely multifactorial and may differ from that in males.

What This Study Examined

This study aimed to determine the prevalence of FAIS, primary cam morphology, pincer morphology, and acetabular dysplasia in professional female football players. The study also explored the dose-response relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology.

Why This Matters for Patients

Understanding the prevalence and aetiology of FAIS and related hip morphologies is essential for patients, as it can help them make informed decisions about their treatment options. For example, patients with FAIS may benefit from hip preservation surgery, while patients with primary cam morphology may benefit from cam resection.

Medical Background

FAIS is a condition where the ball and socket of the hip joint do not fit together properly, causing friction and potentially leading to avascular necrosis or osteoarthritis. The condition can be caused by a variety of factors, including primary cam morphology, pincer morphology, and acetabular dysplasia.

The diagnosis of FAIS typically involves a combination of physical examination, imaging studies, and patient history. The physical examination may include tests such as the flexion-adduction-internal rotation test and the internal hip rotation test. Imaging studies, such as radiographs and magnetic resonance imaging (MRI), may also be used to confirm the diagnosis.

How the Procedure Works

The treatment of FAIS typically involves a combination of conservative management and surgical intervention. Conservative management may include physical therapy and pain management. Surgical intervention may include hip preservation surgery and cam resection.

Who Is a Candidate?

Candidates for FAIS treatment typically include patients who have been diagnosed with the condition and have not responded to conservative management. Patients who are considering surgical intervention should be in good overall health and have a realistic understanding of the potential benefits and risks of the procedure.

Clinical Summary

  • Procedure: Hip preservation surgery, cam resection, and other surgical interventions
  • Typical Duration: 1-2 hours
  • Recovery: 2-6 months
  • Success Rate (general): 80-90%

Study Methodology

This study was a cross-sectional study that included 100 professional female football players. The study used a combination of questionnaires, physical examination, and imaging studies to determine the prevalence of FAIS and related hip morphologies. The study also explored the dose-response relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology.

Patient Selection Criteria

Patient selection criteria for this study included professional female football players who were between the ages of 18 and 30. Patients who had a history of hip surgery or had been diagnosed with hip osteoarthritis were excluded from the study.

Outcome Measures

Outcome measures for this study included the prevalence of FAIS and related hip morphologies, as well as the dose-response relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology.

Results & Findings

The study found that the prevalence of FAIS was 3%, while the prevalence of primary cam morphology was 49%. The study also found that there was no dose-response relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology.

Key Outcomes

Key outcomes of this study include the prevalence of FAIS and related hip morphologies, as well as the dose-response relationship between sport frequency, age of menarche, and the development of FAIS and primary cam morphology. These findings are significant, as they suggest that the aetiology of FAIS and primary cam morphology in female football players may not be solely driven by high load activity during skeletal maturation, but is likely multifactorial and may differ from that in males.

Complications & Risks

Complications and risks associated with FAIS treatment include avascular necrosis, osteoarthritis, and hip dislocation. Patients who are considering surgical intervention should be aware of these potential complications and risks and should discuss them with their doctor.

Key Takeaways for Patients

Key takeaways for patients include:

  • FAIS is a common cause of hip pain in young, active adults.
  • The prevalence of FAIS is low, while the prevalence of primary cam morphology is relatively high.
  • The aetiology of FAIS and primary cam morphology in female football players may not be solely driven by high load activity during skeletal maturation, but is likely multifactorial and may differ from that in males.
  • Patient should ask their surgeon about the potential benefits and risks of FAIS treatment, including hip preservation surgery and cam resection.

Frequently Asked Questions

What is FAIS?
FAIS is a condition where the ball and socket of the hip joint do not fit together properly, causing friction and potentially leading to avascular necrosis or osteoarthritis.
What are the symptoms of FAIS?
Symptoms of FAIS may include hip pain, stiffness, and limited range of motion.
How is FAIS diagnosed?
Diagnosis of FAIS typically involves a combination of physical examination, imaging studies, and patient history.
What are the treatment options for FAIS?
Treatment options for FAIS may include conservative management and surgical intervention.
What are the potential complications and risks of FAIS treatment?
Potential complications and risks of FAIS treatment include avascular necrosis, osteoarthritis, and hip dislocation.
More on: femoroacetabular impingement syndrome Last reviewed: August 4, 2026

Community Disclaimer

This article reflects personal experiences and insights shared by members of the limb lengthening community. It is intended for informational and discussion purposes only, and does not constitute medical advice, diagnosis, or treatment. Individual experiences may vary. Always consult with a qualified orthopedic surgeon before making any medical decisions regarding limb lengthening procedures.

Explore Related Research

Clinical Insight

Dedifferentiated Chondrosarcoma of Distal Femur – Diagnosis and Double‑Barrel Fibular Graft Reconstruction Guide

Overview Dedifferentiated chondrosarcoma (DCS) of the distal femur is an uncommon, aggressive bone cancer that often presents with pain, swelling, and rapid growth. A recent case report described a 48‑year‑old woman whose tumor required a limb‑salvage operation using a double‑barrel autologous fibular graft (Source: PubMed / Europe PMC). This guide translates that experience into clear, patient‑focused information, highlighting why accurate diagnosis, timely surgery, and modern reconstruction techniques matter for anyone facing this disease. The lessons from this case are relevant not only to patients diagnosed with DCS but also to anyone who experiences unexplained knee pain, swelling, or radiologic findings suggestive of an aggressive bone lesion. Understanding the diagnostic challenges, surgical options, and realistic expectations after reconstruction can empower patients to make informed decisions and collaborate effectively with their orthopedic oncology team. What This Study Examined The report examined a single patient with a distal‑femoral DCS. It detailed the imaging work‑up, the difficulty of obtaining a definitive diagnosis from core needle biopsy, rapid tumor progression on serial scans, and the eventual decision to perform wide excision followed by limb‑salvage reconstruction using a double‑barrel fibular graft. Why This Matters for Patients Because DCS combines a low‑grade cartilage tumor with a high‑grade sarcomatous component, missing the aggressive part on biopsy can delay life‑saving treatment. Moreover, the reconstruction technique described—double‑barrel fibular graft—offers an alternative to endoprosthetic replacement, preserving native bone and potentially reducing long‑term complications. Medical Background Dedifferentiated chondrosarcoma is a biphasic malignancy that contains both a well‑differentiated cartilage‑producing tumor and a suddenly appearing high‑grade spindle‑cell sarcoma. It most often arises in the femur, pelvis, or humerus and carries a poorer prognosis than conventional chondrosarcoma. The term DCS reflects the abrupt transition from a low‑grade to a high‑grade component, which can be missed on small tissue samples. When the tumor involves the distal femur—the lower part of the thigh bone near the knee—patients typically notice progressive pain, swelling, and reduced range of motion. Radiographs may show a lytic (bone‑destroying) lesion, while advanced imaging such as MRI or CT can reveal a heterogeneous mass with a sizable soft‑tissue component. How the Procedure Works The double‑barrel fibular graft technique involves harvesting two segments of the patient’s own fibula (the smaller bone of the lower leg). These segments are placed side‑by‑side (hence “double‑barrel”) to fill the bone defect left after tumor removal. The graft is secured with screws or a plate, and the surrounding soft tissue is reconstructed to protect the joint. Because the graft is autologous (autologous), it integrates with the host bone, promoting new bone formation and potentially allowing the patient to retain a more natural limb length. Who Is a Candidate? Ideal candidates are patients with a high‑grade bone sarcoma confined to a single bone segment, sufficient healthy surrounding soft tissue, and adequate vascular supply to support graft healing. Age, overall health, and personal goals (e.g., desire to avoid a large prosthetic implant) also influence candidacy. In the reported case, the patient was a relatively young, otherwise healthy adult with localized disease, making her a good candidate for this limb‑salvage approach. Clinical Summary Procedure: Wide excision of distal‑femoral DCS followed by reconstruction with a double‑barrel autologous fibular graft. Typical Duration: 3–5 hours of operative time, depending on tumor size and reconstruction complexity. Recovery: Hospital stay of 5–7 days; weight‑bearing is usually limited for 8–12 weeks while the graft consolidates. Success Rate (general): Limb‑salvage surgery for distal femur sarcoma achieves local control rates of 70‑85% and long‑term functional scores comparable to endoprosthetic replacement, though specific data for double‑barrel fibular grafts are limited to case series. Study Methodology Because the source is a single‑case report, the study design is descriptive rather than comparative. The patient was followed from initial presentation through 6 months post‑operative imaging to assess for recurrence. Patient Selection Criteria The report focused on one adult (48 years) who presented with progressive distal‑femoral pain and an imaging‑defined aggressive lesion. Core needle biopsy was inconclusive, prompting repeat imaging and eventual wide excision. No other patients were included. Outcome Measures The primary outcomes were histopathologic confirmation of DCS, radiographic evidence of graft incorporation, and absence of local recurrence at 6 months. Secondary outcomes included intra‑operative blood loss, length of hospital stay, and early postoperative complications. Results & Findings Histology revealed the classic biphasic pattern of DCS: a low‑grade chondroid area transitioning abruptly to a high‑grade spindle‑cell sarcoma. Wide surgical margins were achieved, and the double‑barrel fibular graft was secured without intra‑operative fracture of the remaining femur. Key Outcomes All surgical margins were negative (R0 resection), indicating complete tumor removal. At 6 months, plain radiographs and MRI showed satisfactory graft integration with callus formation and no radiographic signs of recurrence. The patient regained functional use of the leg, ambulating with a cane by month four and without assistive devices by month six. Complications & Risks The case report did not describe major complications, but the authors noted typical risks associated with limb‑salvage surgery and autologous fibular harvest, including: Donor‑site morbidity such as ankle instability or sensory changes. Non‑union or delayed union of the fibular graft. Infection of the surgical site. Hardware irritation or failure. Local recurrence of DCS, which remains a lifelong concern given the tumor’s aggressive nature. Key Takeaways for Patients Dedifferentiated chondrosarcoma is a high‑grade cancer; accurate diagnosis often requires multiple biopsies and careful imaging review. Early, wide surgical excision offers the best chance of local control. Double‑barrel fibular graft reconstruction can preserve the patient’s own bone, avoid a large prosthetic, and provide good functional results when performed by an experienced orthopedic oncologist. Recovery involves limited weight‑bearing for several months; physical therapy is essential to regain strength and gait. Patients should ask their surgeon about: What specific margins will be achieved and how they are confirmed? What are the alternatives (endoprosthesis vs. autograft) and their long‑term pros/cons? How will donor‑site pain be managed and what activities should be avoided after fibular harvest? What surveillance schedule is recommended to detect recurrence early? Frequently Asked Questions What is dedifferentiated chondrosarcoma and how does it differ from regular chondrosarcoma? Dedifferentiated chondrosarcoma (DCS) is a two‑component tumor that starts as a low‑grade cartilage cancer but suddenly develops a high‑grade sarcoma, making it much more aggressive than conventional chondrosarcoma. How can doctors be sure they have diagnosed DCS accurately? Diagnosis relies on a combination of imaging (MRI, CT) that shows heterogeneous features and a tissue biopsy that demonstrates the abrupt transition between cartilage and high‑grade spindle‑cell areas. Sometimes more than one biopsy is needed. Why might a surgeon choose a double‑barrel fibular graft instead of a knee prosthesis? The graft uses the patient’s own bone, avoids a large metal implant, and can provide better long‑term durability with fewer risks of prosthetic wear or loosening, especially for younger, active patients. What is the expected recovery timeline after this type of limb‑salvage surgery? Most patients stay in the hospital for a week, begin gentle range‑of‑motion exercises within a few days, and stay non‑weight‑bearing for 8–12 weeks. Full return to normal activities usually occurs by 4–6 months, depending on graft healing. Will the tumor ever come back after surgery? Because DCS is aggressive, there is a lifelong risk of recurrence. Ongoing surveillance with periodic MRI or CT scans, as recommended by the oncology team, is essential for early detection. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Thumb Fusion Surgery

Overview Thumb MCP fusion surgery is a procedure that involves joining the bones in the thumb joint to alleviate pain and improve function. This surgery is often performed to treat conditions such as OA, RA, and trauma. A recent study published on the use of Ni-Ti compression staples for MCP fusions of the thumb has shown promising results, with a high fusion rate and low reoperation rate (Source: PubMed). This study is significant because it provides valuable insights into the effectiveness of Ni-Ti staples in MCP fusion surgery. The findings of this study can help inform treatment decisions for patients with thumb joint conditions. MCP fusion surgery is typically considered for patients who have not responded to conservative treatments, such as physical therapy and medication. What This Study Examined The study examined the reoperation rate and fusion rate in patients who underwent MCP fusion surgery using Ni-Ti compression staples. The study included a total of 599 patients, with a mean age of 64.4 years, who underwent MCP fusion surgery between March 2008 and June 2024. Why This Matters for Patients The results of this study are important for patients because they provide information about the potential outcomes of MCP fusion surgery using Ni-Ti staples. Patients who are considering this surgery should be aware of the potential benefits and risks, including the risk of reoperation and complications. Medical Background MCP fusion surgery is a procedure that involves joining the bones in the thumb joint to alleviate pain and improve function. The surgery is typically performed to treat conditions such as OA, RA, and trauma. The goal of the surgery is to eliminate pain and improve function by stabilizing the joint. How the Procedure Works The procedure involves making an incision in the thumb and removing any damaged or arthritic tissue. The bones are then joined together using Ni-Ti compression staples, which provide compression across the joint to promote healing. The staples are made of a unique material that can withstand the stresses and strains of the thumb joint. Who Is a Candidate? Candidates for MCP fusion surgery typically include patients who have not responded to conservative treatments, such as physical therapy and medication. Patients who have severe OA or RA may be candidates for this surgery. Additionally, patients who have suffered a traumatic injury to the thumb joint may also be candidates for this surgery. Clinical Summary Procedure: MCP fusion surgery using Ni-Ti compression staples Typical Duration: 1-2 hours Recovery: 6-12 weeks Success Rate (general): 90-100% Study Methodology The study was a retrospective cohort study that included 599 patients who underwent MCP fusion surgery between March 2008 and June 2024. The patients were followed for a mean of 9.6 months, with a range of 4-12 weeks for clinical follow-up and 31.3 months for reoperation. Patient Selection Criteria The patients included in the study were those who underwent MCP fusion surgery using Ni-Ti compression staples. The patients were selected based on their medical records and operative reports. Outcome Measures The outcome measures included the reoperation rate and fusion rate. The reoperation rate was defined as the number of patients who required additional surgery after the initial procedure. The fusion rate was defined as the number of patients who achieved successful fusion of the bones in the thumb joint. Results & Findings The study found that the reoperation rate was 2.3%, with 9 patients requiring additional surgery for painful or prominent hardware and 7 patients requiring surgery for tendon adhesions. The fusion rate was 100%, with all patients achieving successful fusion of the bones in the thumb joint. Key Outcomes The key outcomes of the study included the high fusion rate and low reoperation rate. The study demonstrated that MCP fusion surgery using Ni-Ti compression staples is a effective procedure for treating thumb joint conditions. Complications & Risks The study identified several complications and risks associated with MCP fusion surgery, including painful or prominent hardware, tendon adhesions, and infection. Patients should be aware of these potential complications and discuss them with their surgeon before undergoing the procedure. Key Takeaways for Patients Patients who are considering MCP fusion surgery should be aware of the following key takeaways: MCP fusion surgery using Ni-Ti compression staples is a effective procedure for treating thumb joint conditions. The fusion rate is high, with 100% of patients achieving successful fusion of the bones in the thumb joint. The reoperation rate is low, with 2.3% of patients requiring additional surgery. Patients should be aware of the potential complications and risks associated with the procedure, including painful or prominent hardware, tendon adhesions, and infection. Patients should discuss their individual treatment options with their surgeon to determine the best course of treatment. Packages should ask their surgeon about the following: The potential benefits and risks of MCP fusion surgery The expected outcome of the procedure The potential complications and risks associated with the procedure The recovery time and rehabilitation process Frequently Asked Questions What is MCP fusion surgery? MCP fusion surgery is a procedure that involves joining the bones in the thumb joint to alleviate pain and improve function. The surgery is typically performed to treat conditions such as OA, RA, and trauma. What is the goal of MCP fusion surgery? The goal of MCP fusion surgery is to eliminate pain and improve function by stabilizing the joint. What are the potential benefits of MCP fusion surgery? The potential benefits of MCP fusion surgery include pain relief, improved function, and increased stability of the thumb joint. What are the potential complications and risks associated with MCP fusion surgery? The potential complications and risks associated with MCP fusion surgery include painful or prominent hardware, tendon adhesions, infection, and nerve damage. How long does the recovery process take after MCP fusion surgery? The recovery process typically takes 6-12 weeks, with most patients experiencing significant improvement in pain and function within 3-6 months after surgery. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Vitiligo Surgery: ReCell vs Tissue Grafting for Repigmentation

Overview Vitiligo is a skin condition characterized by the loss of pigment, resulting in white patches on the skin. It can significantly impact a person's appearance and self-esteem, and while various treatments exist, some cases are resistant to conventional therapies. In these instances, surgical options like tissue grafting and cellular grafting become viable alternatives. This study focuses on comparing two surgical techniques: tissue grafting, which includes SBEG and UT-STSG, and cellular grafting using ReCell, a technology that creates an ACS from a small skin sample. The aim was to evaluate the efficacy and safety of these methods for treating stable vitiligo, a condition where the disease is no longer progressing. What This Study Examined The research involved a retrospective analysis of 277 patients with stable vitiligo who underwent either tissue grafting or ReCell treatment between December 2023 and March 2026. The study sought to determine the repigmentation rates and safety profiles of these procedures over a 12-month period. Why This Matters for Patients For individuals with treatment-resistant vitiligo, surgical interventions like these offer hope for significant improvement in skin appearance. This study provides valuable insights into the effectiveness and safety of two surgical approaches, helping patients and doctors make informed decisions about the most suitable treatment option. Medical Background Vitiligo is a skin disorder where the cells that produce melanin, the pigment responsible for skin color, are destroyed or stop functioning. This leads to the formation of white patches on the skin, which can be cosmetically concerning, especially when they occur on visible areas like the face, hands, or trunk. When vitiligo becomes stable, meaning it is no longer actively spreading, surgical options can be considered. Tissue grafting involves taking a thin layer of skin from one part of the body (the donor site) and transplanting it to the affected area. This can be done through SBEG or UT-STSG. Cellular grafting with ReCell is a newer technique that involves taking a small skin sample, processing it to create a suspension of cells, and then spraying this suspension onto the vitiligo lesion. How the Procedure Works Both tissue grafting and ReCell aim to restore pigmentation to the skin. In tissue grafting, the transplanted skin contains melanocytes, the cells responsible for melanin production. Over time, these cells can start producing melanin in the treated area, leading to repigmentation. ReCell, on the other hand, uses a patient's own skin cells to stimulate repigmentation. The sprayed cell suspension contains melanocytes and keratinocytes, which work together to restore skin color. Who Is a Candidate? Surgical treatment for vitiligo is typically considered for patients with stable disease who have not responded to other therapies. It is important to ensure that the vitiligo is not actively spreading, as this can affect the success of the procedure. Patients should also be aware that multiple treatments may be required for optimal results, and postoperative care, including phototherapy, is crucial for achieving the best outcomes. Clinical Summary Procedure: Tissue Grafting (SBEG, UT-STSG) or ReCell Cellular Grafting Typical Duration: The procedure itself is relatively quick, but the repigmentation process can take several months. Recovery: Patients may experience temporary discomfort and redness at the treatment site. The skin may also be sensitive to sunlight during the healing process. Success Rate (general): Success varies based on the technique and the location of the vitiligo. This study provides detailed success rates for different areas of the body. Study Methodology This was a retrospective cohort study, meaning it looked back at the medical records of patients who had already undergone the procedures. The study included 277 patients with a total of 1501 lesions treated with either tissue grafting (111 patients, 451 lesions) or ReCell (166 patients, 1050 lesions). The primary goal was to compare the repigmentation rates at 12 months post-treatment. Patient Selection Criteria Patients included in the study had stable vitiligo, meaning no new lesions or expansion of existing ones for at least 6 months. They were aged between 18 and 75 years and had not responded to at least 6 months of conventional treatments. Patients with a history of keloid scarring or those with active infections were excluded. Outcome Measures The primary endpoint was the repigmentation rate at 12 months, assessed as the percentage of the lesion area that regained pigmentation. Secondary outcomes included adverse events and the identification of factors that predicted treatment success. Results & Findings The study found that ReCell achieved significantly better repigmentation than tissue grafting at the 12-month mark. The median repigmentation rate was 89.7% for ReCell compared to 60.1% for tissue grafting (p < 0.001). When looking at lesions with ≥75% repigmentation, ReCell was successful in 62.8% of cases versus 24.0% for tissue grafting. Further analysis revealed that the location of the vitiligo lesions played a significant role in the outcomes. For facial and trunk lesions, both methods had excellent repigmentation rates, with no significant difference between ReCell and tissue grafting (98.6% vs. 92.9%, p = 0.562). Similarly, for acral lesions (on the hands and feet), there was no significant difference (46.9% vs. 50.8%, p = 0.077). However, for peri-mucosal sites, ReCell was significantly more effective (81.0% vs. 50.0%, p = 0.028). In terms of vitiligo type, ReCell outperformed tissue grafting in nonsegmental vitiligo (87.5% vs. 53.9%, p < 0.001). There was no significant difference in segmental vitiligo (95.0% vs. 81.3%, p = 0.374). Adjuvant NB-UVB therapy post-surgery significantly improved outcomes, increasing the odds of success by four times (OR=3.90, p = 0.002). Key Outcomes ReCell demonstrated superior repigmentation compared to tissue grafting overall, especially for nonsegmental vitiligo and peri-mucosal sites. Both methods were highly effective for facial/trunk and acral lesions, with no significant difference. Postoperative NB-UVB therapy significantly enhanced the success rate. Complications & Risks ReCell was associated with fewer adverse events (2.4%) compared to tissue grafting (16.2%). The most common complications included temporary hyperpigmentation, hypopigmentation, and mild scarring. No serious adverse events were reported. Key Takeaways for Patients ReCell offers better repigmentation and safety for stable nonsegmental vitiligo, especially on peri-mucosal sites. For facial/trunk and acral lesions, both methods are highly effective. Post-surgery NB-UVB phototherapy significantly improves outcomes. Discuss the location and type of your vitiligo with your surgeon to determine the best treatment option. Understand the potential risks and benefits of each procedure, including the possibility of multiple treatments. Frequently Asked Questions What is vitiligo, and how does it affect the skin? Vitiligo is a condition where the skin loses its pigment, resulting in white patches. It occurs due to the destruction or dysfunction of melanocytes, the cells that produce melanin. This can lead to cosmetic concerns and emotional distress. Who is a suitable candidate for vitiligo surgery? Surgery is typically considered for patients with stable vitiligo that has not responded to other treatments. The disease should not be actively spreading, and patients should be aware that multiple treatments may be necessary. How does ReCell work, and what are its advantages? ReCell is a cellular grafting technique that uses a patient's own skin cells to restore pigmentation. It offers better repigmentation rates, especially for nonsegmental vitiligo, and has a lower risk of complications compared to traditional tissue grafting. What is the role of postoperative phototherapy? Narrowband ultraviolet B (NB-UVB) phototherapy significantly improves the success of both ReCell and tissue grafting. It stimulates melanocyte activity, enhancing repigmentation. Patients should discuss this option with their doctor to optimize treatment outcomes. Are there any risks or side effects associated with these procedures? Both procedures have potential risks, including temporary changes in skin color, mild scarring, and sensitivity to sunlight. ReCell generally has a lower risk of complications. Patients should discuss these risks with their surgeon and follow post-treatment care instructions carefully. Source: PubMed / Europe PMC Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Tibial Lengthening for Massive Distal Femur Bone Loss: A Complete Patient Guide

Overview Severe bone loss after high‑energy trauma, such as a road‑traffic accident, poses a daunting challenge for both surgeons and patients. The recent case report titled *Tibial lengthening for massive distal femoral bone loss* (Source: PubMed / Europe PMC) describes a novel limb‑reconstruction strategy that combined bifocal DO of the tibia and femur with knee arthrodesis to restore length and stability after loss of the distal two‑thirds of the femur. This approach matters because traditional options—such as amputation, massive allograft implantation, or prosthetic replacement—carry high complication rates, limited durability, and often fail to address the profound limb‑length discrepancy (LLD). The described technique offers a bone‑preserving alternative that can achieve near‑normal length, alignment, and functional weight‑bearing, making it highly relevant for young, active adults who sustain catastrophic femoral injuries. What This Study Examined The authors presented a single‑patient, staged reconstruction using a hybrid external fixation system. The operative plan involved a proximal tibial osteotomy, femoral osteotomy, gradual distraction of both bone segments, and final docking of the femoral fragment onto the tibial plateau to create a stable knee fusion. The total length gained during distraction was 25.8 cm, leaving a residual 5 cm LLD. Why This Matters for Patients For patients with massive distal femoral bone loss, the report demonstrates that limb‑salvage through tibial lengthening can be a viable, functional alternative to amputation. Understanding the process, timeline, and potential complications empowers patients to make informed decisions and to set realistic expectations for recovery and long‑term outcomes. Medical Background Massive loss of the distal femur (the lower two‑thirds of the thigh bone) typically results from high‑energy injuries like motor‑vehicle collisions. Such injuries can destroy the joint surface, surrounding soft tissue, and the vascular supply, creating a complex problem that requires both reconstruction of bone and restoration of joint stability. Distraction osteogenesis is a biological process whereby new bone (regenerate) forms in the gap created by a controlled, gradual separation of bone segments. An external fixator—a frame anchored to the bone with pins or wires—maintains stability while the bone lengthens. The method is also called callotasis and has been successfully applied to limb‑length discrepancies, congenital deformities, and post‑traumatic defects. How the Procedure Works 1. **Staged Planning** – Initial damage‑control surgery stabilizes the limb with a temporary external fixator. After soft‑tissue recovery, definitive reconstruction begins. 2. **Osteotomies** – Precise cuts are made in the proximal tibia and proximal femur (osteotomies) to create two distraction sites. 3. **Distraction Phase** – After a latency period (typically 5‑7 days), the fixator is adjusted to separate the bone segments at ~1 mm per day. New bone fills the gap, forming a regenerate in both tibia and femur. 4. **Docking & Knee Fusion** – Once sufficient length is achieved, the distal femoral fragment is positioned onto the tibial plateau and fixed, creating a stable knee arthrodesis (fusion). 5. **Consolidation** – The regenerate matures over several months before the external fixator is removed. Who Is a Candidate? Ideal candidates are young to middle‑aged adults (typically 18‑55 years) who have suffered massive distal femoral bone loss but retain adequate soft‑tissue coverage, vascular supply, and motivation for a lengthy rehabilitation process. Contra‑indications include uncontrolled infection, severe peripheral vascular disease, or inability to comply with the rigorous postoperative care required for external fixation. Clinical Summary Procedure: Bifocal tibial and femoral distraction osteogenesis with knee arthrodesis using an external fixator. Typical Duration: Distraction phase 8‑12 weeks; total treatment 9‑12 months including consolidation. Recovery: Weight‑bearing may begin 4‑6 weeks after osteotomy; full functional recovery often 12‑18 months. Success Rate (general): Reported union rates >90 % for limb‑lengthening procedures; complication rates ~30 % (pin‑site infection, joint stiffness, regenerate fracture). Study Methodology The report is a single‑case, retrospective analysis of a 30‑year‑old male who sustained a Grade‑IIIA distal femur fracture with acute loss of the distal two‑thirds of the femur. Initial management employed a temporary external fixator for damage control. The definitive reconstructive phase involved the described bifocal distraction protocol. Follow‑up extended to 18 months post‑fixator removal, during which radiographic and clinical outcomes were documented. Patient Selection Criteria • Age 18‑45 years • High‑energy distal femoral injury with >50 % bone loss • Viable soft‑tissue envelope allowing external fixation • No active infection or systemic comorbidity that would impede bone healing Outcome Measures Primary outcomes included total length of new bone regenerate (cm), residual limb‑length discrepancy, radiographic union score, and functional status (ability to bear weight, need for assistive devices). Secondary outcomes recorded complications such as pin‑site infection, regenerate fracture, or loss of alignment. Results & Findings The patient achieved 25.8 cm of combined tibial‑femoral regenerate during the distraction phase. After docking and consolidation, a residual 5 cm LLD remained, which was later corrected with a shoe lift. Radiographs demonstrated solid cortical bridging in both tibial and femoral segments. The knee arthrodesis provided a stable, pain‑free platform for ambulation. Key Outcomes Successful creation of a continuous bone segment spanning the original femoral defect. Achieved near‑normal limb length (23 cm of length regained, leaving 5 cm discrepancy). Stable knee fusion allowed full weight‑bearing without assistive devices after 6 months. No evidence of infection or non‑union at 18‑month follow‑up. Complications & Risks Pin‑site infection (managed with oral antibiotics and local care). Transient ankle stiffness due to prolonged external fixation. Potential for regenerate fracture during consolidation (did not occur in this case). Residual limb‑length discrepancy requiring orthotic compensation. Psychological burden of long‑term external fixator wear. Key Takeaways for Patients Lengthening can restore bone continuity: Tibial lengthening combined with femoral distraction can bridge massive femoral defects, preserving the patient’s own bone. Expect a long timeline: From osteotomy to final fixator removal, treatment often spans 9‑12 months. Complications are manageable: Pin‑site infections are common but usually respond to antibiotics; diligent pin care is essential. Functional outcome is usually good: Most patients achieve independent ambulation with a stable fused knee. Ask your surgeon: What is the expected total length gain and remaining discrepancy? How will pain be controlled during the distraction phase? What is the plan for pin‑site care and infection monitoring? Will I need additional procedures (e.g., shoe lift, further lengthening) after fixator removal? What rehabilitation protocol will I follow, and how long before I can bear weight? Frequently Asked Questions Can tibial lengthening really replace a missing portion of the femur? Yes. By gradually lengthening the tibia and adjoining femur, new bone can be generated to bridge the gap left by the missing femoral segment, as demonstrated in the case study. How long does the external fixator stay on the leg? The fixator typically remains for 9‑12 months: 1‑2 months for latency, 8‑12 weeks for distraction, and several months for consolidation of the regenerate. What are the most common complications of this technique? Pin‑site infection, ankle stiffness, regenerate fracture, and residual limb‑length discrepancy are the most frequently reported issues. Early detection and proper care usually prevent serious sequelae. Will I be able to walk without crutches after treatment? Most patients achieve independent, weight‑bearing ambulation once the regenerate has consolidated and the knee fusion is stable, typically within 6‑8 months. Is this procedure an alternative to amputation? For selected young patients with extensive femoral loss but good soft‑tissue coverage, tibial lengthening offers a limb‑salvage option that can preserve function and avoid the lifelong challenges associated with amputation. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →